Earnings

ANI Pharmaceuticals Raises FY2026 Adj EPS Guidance from $9.19-$9.69 to $9.37-$9.71 vs $9.26 Est; Narrows FY2026 Sales Guidance from $1.080B-$1.140B to $1.085B-$1.125B vs $1.102B Est

Nov 5, 2026 · 06:52 AM ET· updated 56m ago

ANI Pharmaceuticals (NASDAQ:ANIP) raises FY2026 Adj EPS guidance from $9.19-$9.69 to $9.37-$9.71 vs $9.26 analyst estimate. Narrows FY2026 sales outlook from $1.080 billion-$1.140 billion to $1.085 billion-$1.125

Why It Matters

ANI Pharmaceuticals raised its profit forecast for next year slightly. The company narrowed its sales range, showing more confidence in its plan.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ANIP72.51

+0.86 (+1.20%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.